

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Abattis Bioceuticals Corp.
Suite 1000, 355 Burrard Street
Vancouver BC V6C 1N5

Phone: 778-908-6650 Fax: 604-538-6658

Item 2. Date of Material Change

December 12, 2012

Item 3. News Release

A News Release dated and issued December 12, 2012 at Vancouver, British Columbia, through Stockwatch, Baystreet and SEDAR.

Item 4. Summary of Material Change

See news release, a copy of which is attached hereto.

Item 5. Full Description of Material Change

See news release, a copy of which is attached hereto.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Mike Withrow, President & CEO
Telephone: 778-908-6650

Item 9. Date of Report

December 12, 2012



Abattis Closes Private Placement

VANCOUVER, British Columbia (December 12, 2012)—Abattis Bioceuticals Corp. (CNSX: FLU) (the “Company”) is pleased to announce that further to its news release of November 29, 2012, the Company has now completed its private placement and has issued an aggregate of 2,100,000 units at a price of \$0.05 per unit for gross proceeds of \$105,000. The Company paid \$4,400 in cash compensation in relation to this financing.

All securities issued pursuant to this private placement are subject to a four month hold period expiring on April 13, 2013.

The proceeds raised in this private placement will be used by the Company for general working capital.

About Abattis Bioceuticals Corp.

Abattis Bioceutical Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients for use in BioPharma, Nutraceutical, Cosmetic and Animal Nutrition markets. The company has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company’s website at www.abattis.com.

ON BEHALF OF THE COMPANY

"Mike Withrow"

Mike Withrow

President, CEO and Director

*Neither the CNSX Exchange nor its regulations services accepts responsibility
for the adequacy or accuracy of this release.*